Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases: A Single-Center, Single-Arm, Open-Label Clinical Study (PRICE)

This study attempts to employ a combination therapy using rhG-CSF, IL-2, and PD-1 inhibitors, aiming to overcome the limitations of monotherapy in immunotherapy through multi-faceted immune regulation. By modulating the immune microenvironment to enhance immune cell infiltration, and breaking through the physical and immunosuppressive barriers of tumors, it seeks to augment the efficacy of immunotherapy. This approach explores the effectiveness of a neoadjuvant treatment model in cases of liver metastasis.

开始日期2024-07-10

申办/合作机构

南京医科大学第三附属医院

EUCTR2019-001696-36-IT / Not yet recruiting临床2期IIT

Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG) - IL2REG

开始日期2019-10-09

申办/合作机构

Ospedale San Raffaele Srl

NCT02467504 / Completed临床2期IIT

A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Methotrexate (MTX)-Naive Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, characterized by symmetric poly-arthritis usually involving the small joints of the hands and feet. In addition, various extra-joint manifestations may develop. Several immunomodulating agents have been attempted in the treatment of RA without achieving satisfactory results. Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (IL-2). The investigators hypothesized that low-dose IL-2 could be a novel therapy in active RA patients. This clinical study will test the efficacy and safety of low dose IL-2 treatment in RA. The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in RA. The investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for RA by randomized controlled study (hrIL-2 (N = 23) + Methotrexate (MTX)+ Loxoprofen versus placebo+MTX + Loxoprofen group (N = 24)).

开始日期2015-07-01

申办/合作机构

北京大学人民医院

[+2]

100 项与重组人白介素-2 (北京双鹭药业) 相关的临床结果

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的转化医学

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的专利（医药）

登录后查看更多信息

100 项与重组人白介素-2 (北京双鹭药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AC01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肿瘤	中国	北京双鹭药业股份有限公司	1999-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性干燥综合征	临床2期	中国	北京双鹭药业股份有限公司	2015-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02467504 (CTgov)	临床2期	类风湿关节炎	47	Loxoprofen+Folic Acid+MTX+hrIL-2 active (Experimental)	願憲齋製觸遞構築憲製(衊顧鹽淵獵憲蓋艱網蓋) = 蓋齋選願鬱觸壓餘觸繭齋淵襯構襯選鏇鬱繭鏇 (簾築鬱觸壓窪願衊願構, 蓋鬱艱構觸選夢簾憲觸 ~ 鑰網壓願餘積積壓餘衊) 更多	-	2019-09-09
				hrIL-2 placebo+Loxoprofen+Folic Acid+MTX (Placebo Comparator)	願憲齋製觸遞構築憲製(衊顧鹽淵獵憲蓋艱網蓋) = 範選襯窪選製顧築壓壓齋淵襯構襯選鏇鬱繭鏇 (簾築鬱觸壓窪願衊願構, 蓋餘衊餘餘憲鏇艱築窪 ~ 廠築廠鬱簾簾簾鑰憲壓) 更多